Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements
Stephen R. Marder(West Los Angeles College), David G. Daniel, Alan Kott, Dawn I. Velligan(The University of Texas at San Antonio Health Science Center), Michael Davidson(Sheba Medical Center), R. Luthringer(Max Planck Institute for Developmental Biology), Xingmei Wang(University of Pennsylvania), Daniel Umbricht(Centre for Addiction and Mental Health)
Cited by 11
Related Papers
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
|American Journal of Psychiatry|2016|1.1k
Self-report measures of medication adherence behavior: recommendations on optimal use
|Translational Behavioral Medicine|2015|832
Beyond hypofrontality: A quantitative meta‐analysis of functional neuroimaging studies of working memory in schizophrenia
|Human Brain Mapping|2005|622
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research
|Pharmacoepidemiology and Drug Safety|2006|611